Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck Cancer
Status:
Recruiting
Trial end date:
2028-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial evaluates the safety and effectiveness of using two imaging techniques,
indium In 111 panitumumab (111In-panitumumab) with single photon emission computed tomography
(SPECT)/computed tomography (CT) and panitumumab-IRDye800 fluorescence imaging during surgery
(intraoperative), to detect disease in patients with head and neck cancer. 111In-panitumumab
is an imaging agent made of a monoclonal antibody that has been labeled with a radioactive
molecule called indium In 111. The agent targets and binds to receptors on tumor cells. This
allows the cells to be visualized and assessed with SPECT/CT imaging techniques. SPECT is
special type of CT scan in which a small amount of a radioactive drug is injected into a vein
and a scanner is used to make detailed images of areas inside the body where the radioactive
material is taken up by the cells. CT is an imaging technique for examining structures within
the body by scanning them with x-rays and using a computer to construct a series of
cross-sectional scans along a single axis. Panitumumab-IRDye800 is an imaging agent composed
of panitumumab, a monoclonal antibody, linked to a fluorescent dye called IRDye800. Upon
administration, panitumumab-IRDye800 targets and binds to receptors on tumor cells. This
allows the tumor cells to be detected using fluorescence imaging during surgery. Adding
111In-panitumumab SPECT/CT imaging to intraoperative panitumumab-IRDye800 fluorescence
imaging may be more effective at detecting disease in patients with head and neck cancer.